Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Roch Houot, Pablo Arija, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Cedric Portugues, Catherine Thieblemont, Markqayne Ray, Yin Yang, Sante Cundari, Camille Linot, Divyesh Mistry, Martijn Simons, Anna Gittfried, François Lemonnier

Blood (2025) 146 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2025-3714

Published: 2025

Journal Articles

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Emmanuel Bachy, Sattva S. Neelapu, Julio C. Chavez, Ibrahim Yakoub-Agha, Christine Lui, Jacob Wulff, Harry Miao, Olga Nikolajeva, Timothy Best, Camille Linot, Caron A. Jacobson

Blood (2023) 142 (Supplement 1): 4865.

https://doi.org/10.1182/blood-2023-175055

Published: 2023